期刊
WORLD ALLERGY ORGANIZATION JOURNAL
卷 6, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1939-4551-6-6
关键词
Atopic dermatitis; Eczema; Therapy; Guideline
资金
- Astellas
- Basilea
- Galderma
- GSK
- Loreal
- MEDA
- Merck
- Novartis
- Pierre Fabre
- MSD
Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and thus justify additional antimicrobial / antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength. Eczema school educational programs have been proven to be helpful.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据